{"abstract": "The biotech giant Amgen is near a deal to buy Onyx Pharmaceuticals, a maker of cancer-fighting drugs, for about $125 a share, people briefed on the matter said on Saturday.", "web_url": "https://dealbook.nytimes.com/2013/08/24/amgen-said-to-be-near-a-deal-to-buy-onyx/", "snippet": "The biotech giant Amgen is near a deal to buy Onyx Pharmaceuticals, a maker of cancer-fighting drugs, for about $125 a share, people briefed on the matter said on Saturday.", "lead_paragraph": "Updated, Aug. 25, 7:38 p.m. | Amgen announced on Sunday that it has agreed to buy Onyx for $125 a share. ", "print_section": "A", "print_page": "20", "source": "The New York Times", "multimedia": [], "headline": {"main": "Amgen Said to Be Near Deal to Buy Onyx for $10.5 Billion", "kicker": "DealBook", "content_kicker": null, "print_headline": "Amgen Is Said to Be Near a $10.5 Billion Deal to Buy Onyx", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "organizations", "value": "AMGEN INC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Onyx Pharmaceuticals", "rank": 4, "major": "N"}], "pub_date": "2013-08-24T17:58:58+0000", "document_type": "article", "news_desk": "", "section_name": "Business Day", "byline": {"original": "By Michael J. de la Merced and Andrew Pollack", "person": [{"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/d09cb36d-6286-5bf4-95aa-f46cde3f78d3", "word_count": 644, "uri": "nyt://article/d09cb36d-6286-5bf4-95aa-f46cde3f78d3"}